Announcements Trials
Browse Landscape

Phase

Phase 2 68Phase 1 26Phase 1/2 19Phase NA 8Phase EARLY_PHASE1 5Phase 3 4Phase 4 3

Status

Completed 25Unknown 9Recruiting 9Not yet recruiting 7Withdrawn 3Active not recruiting 3Terminated 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 16Breast 12Tumor-Agnostic 5Thoracic 5Lymphoid 5Genitourinary 4CNS 4Plasma cell 3Other hematologic neoplasm 3Head & Neck 3Dermatologic 3Classical hematology 3Gynecologic 2Other 1NET 1Myeloid 1Endocrine 1

Conditions

Multiple Myeloma 3Neoplasms 1Back Pain 1

Interventions

pomalidomide 1ixazomib 1Zoledronic Acid 1Lenalidomide 1Kyphoplasty 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Withdrawn × Plasma cell × Clear all
NCT05183139 2022-05-03

US MM-7

Takeda

Phase 4 Withdrawn
Plasma cell

Multiple Myeloma

NCT01410929 2017-01-20

MM

Merit Medical Systems, Inc.

Phase 4 Withdrawn
Plasma cell

Back Pain, Multiple Myeloma, Neoplasms

NCT00242528 2015-04-14

Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.

Novartis

Phase 4 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡